Back to search results
NCT06765707

Symptom Monitoring Using Patient-Report to Improve Medication Use

Enrolling by Invitation
NAAges 18+InterventionalSupportive care
Medical College of Wisconsin
~225 participants
Updated 2025-07-24 on ClinicalTrials.gov
What's tested:Pharmacist delivered symptom monitoring and management

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Medication adherence
Measured over From baseline to 12 months
+1 more outcome measured

Conditions

Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Endocrine Therapy

Explore related trials

Breast CarcinomaHR LYSINE DEMETHYLASE AND NUCLEAR RECEPTOR COREPRESSOR

NCT06765707

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic

    Rochester, Minnesotano site contact published

  • Medical College of Wisconsin

    Milwaukee, Wisconsinno site contact published

  • University of Illinois Chicago

    Chicago, Illinoisno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Cisgender women assigned female at birth
Age 18 years or older
Stage 1-3 hormone receptor-positive breast cancer
Recommended to continue AET for ≥2 additional years after enrollment
Low adherence defined as prescription fills with a proportion of days covered (PDC) of \<80%, examined over all fills during the 2 years prior to date of eligibility review since the first AET prescription/data of AET start OR unable to calculate adherence
Verbal fluency in English or Spanish
Ability to understand informed consent and the willingness to sign it

Exclusion

Unable to verbalize comprehension of study or impaired decision-making
Known distant metastatic disease
Not receiving breast cancer care or AET prescription from provider at participating site
Evidence that an oncology provider discontinued their AET
Pregnant or trying to get pregnant
Facility-administered medications (i.e., nursing home, home healthcare agency)

What this trial measures

  • Medication adherenceFrom baseline to 12 months

    Defined as the proportion of total days' pills taken by patients measured by the opening of an electronic pill monitoring cap

  • Intervention durability on medication adherenceFrom 12 to 24 months

    Assess the durability of AET adherence 1 year post intervention on patients assigned to the intervention phase first. Defined as the proportion of total days' pills taken by patients measured by the opening of an electronic pill monitoring cap